Lake Street analyst Frank Takkinen initiated coverage of Hyperfine (HYPR) with a Buy rating and $1.50 price target Hyperfine’s ultra-low field MR imaging system, Swoop, provides diagnostic quality brain imaging at the bedside and the company is also collecting clinical data to support use in new indications and settings of care to expand the total addressable market, the analyst tells investors. The firm believes “a robust foundation has been built,” with new indications expected to drive growth and margin expansion, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYPR:
- Hyperfine price target lowered to $1.20 from $1.50 at B. Riley
- Hyperfine Inc. Faces Potential Stock Price Decline Amid $150 Million Securities Sale Plan
- Hyperfine Inc. Earnings Call: Growth Amid Challenges
- Hyperfine, Inc. Reports 2024 Financial Results and Strategic Expansion
- Hyperfine sees FY25 revenue growth 20%- 30% over 2024, consensus $17M